CDK4 and neoplasm: This trend aligned with in vivo assays, in which tumor growth in HR+/HER2-low breast cancer xenografted mice administered CDK4/6 inhibitor combined with endocrine therapy exhibited decreased efficacy relative to the HR+/HER2-0 subtype (P < 0.05) (Fig. 2C–E).